Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cyclopharm Limited ( (AU:CYC) ) has issued an update.
Cyclopharm Limited addressed an ASX inquiry regarding an increase in the price and volume of its securities, stating that it is not aware of any undisclosed information affecting trading. The company confirmed that it continues to operate within its strategic and commercial plans and complies with ASX listing rules.
More about Cyclopharm Limited
Cyclopharm Limited operates in the healthcare industry, focusing on the development and commercialization of nuclear medicine technologies, including their primary product, Technegas, which is used for lung imaging.
YTD Price Performance: 1.27%
Average Trading Volume: 44,505
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$177.8M
For a thorough assessment of CYC stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue